H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on ...

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings NEW YORK, January 27, 2025--(BUSINESS WIRE)--H.C.

On Tuesday, H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a price target of $180.00. According to InvestingPro data, this ...